Tag: tamoxifen
Tamoxifen: A type of endocrine treatment that interferes with a tumor's ability to use estrogen. Tamoxifen is prescribed for both premenopausal and postmenopausal women with estrogen receptor positive (ER+) breast cancer or at high risk for it.
Articles
News
Foods
Studies
- (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line
- A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up
- Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
- Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer
- Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
- Amurensin G inhibits angiogenesis and tumor growth of tamoxifen-resistant breast cancer via Pin1 inhibition
- An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs)
- Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients
- Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor--dependent and estrogen receptor--independent mechanisms
- Aromatase inhibitor and tamoxifen's impact on breast cancer recurrence among survivors in a large HMO
- Aromatase inhibitors and cardiac outcomes in women undergoing cardiac angiography after early breast cancer
- Association between Alcohol Intake and Serum Sex Hormones and Peptides Differs by Tamoxifen Use in Breast Cancer Survivors
- Association between race and BMI with response to neoadjuvant endocrine therapy in postmenopausal women with large estrogen receptor-positive breast cancers
- Association between tamoxifen treatment and diabetes
- Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
- Bisphenol A Increases Mammary Cancer Risk in Two Distinct Mouse Models of Breast Cancer
- Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study
- Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy
- Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression
- Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
- Breast Cancer and Obesity: In Vitro Interferences between Adipokines and Proangiogenic Features and/or Antitumor Therapies?
- Breast cancer in the very elderly: Staging, treatment, and outcomes in patients over age 80
- Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment
- Breast Cancer Recurrence in Older Women Five to Ten Years after Diagnosis
- Breast cancer recurrence risk in relation to antidepressant use after diagnosis
- Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
- Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2—3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
- Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial
- Changes in Weight and Body Composition in Women Receiving Chemotherapy for Breast Cancer
- Chemopreventive effect of green tea extract and tamoxifen on mouse mammary preneoplastic lesions
- Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status
- Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
- Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis
- Combined treatment of breast cancer cells with epigallocatechin gallate (EGCG) and Tamoxifen delays cell-growth in long-term culture: Implications for recurrent breast cancer
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole
- Comparison of Tamoxifen with Edible Seaweed (Eucheuma cottonii L.) Extract in Suppressing Breast Tumor
- Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study
- Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6
- Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9
- CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- Deep Time: The Long and the Short of Adjuvant Endocrine Therapy for Breast Cancer
- Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol
- Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?
- Dual Estrogen Effects on Breast Cancer: Endogenous Estrogen Stimulates, Exogenous Estrogen Protects. Further Investigation of Estrogen Chemoprevention Is Warranted
- Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes
- Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma
- Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
- Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial
- Effect of early discontinuation and nonadherence to adjuvant hormone therapy on mortality in women with breast cancer
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
- Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
- Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: Possible role of cytochrome p450 3A4 and P-glycoprotein inhibition by baicalein
- Effects of dietary omega-3 and omega-6 in the prevention of rat mammary cancer with tamoxifen
- Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis
- Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
- Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator
- EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein
- Endocrine therapy in obese patients with primary breast cancer: another piece of evidence in an unfinished puzzle
- Estradiol, Tamoxifen, and Flaxseed Alter IL-1β and IL-1Ra Levels in Normal Human Breast Tissue in Vivo
- Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users
- Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer
- Fish Oil Alters Tamoxifen-Modulated Expression of mRNAs That Encode Genes Related to Differentiation, Proliferation, Metastasis, and Immune Response in Rat Mammary Tumors
- Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice
- Fracture Risk in Older, Long-Term Survivors of Early-Stage Breast Cancer
- Fucoidan Extract Enhances the Anti-Cancer Activity of Chemotherapeutic Agents in MDA-MB-231 and MCF-7 Breast Cancer Cells
- Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation
- Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells
- Hair shaft abnormalities after chemotherapy and tamoxifen therapy in breast cancer patients evaluated by optical coherence tomography
- HDAC inhibitors trigger the autophagic switch from prosurvival to prodeath in tamoxifen-treated breast cancer cells
- Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer
- Improvement in self-reported physical health predicts longer survival among women with a history of breast cancer
- In vivo and in vitro demonstration of herb-drug interference in human breast cancer cells treated with tamoxifen and trastuzumab
- Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
- Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis
- Influence of Tangeretin on Tamoxifen's Therapeutic Benefit in Mammary Cancer
- Inhibition of tamoxifen's therapeutic benefit by tangeretin in mammary cancer
- Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice
- Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
- Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis
- Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging
- Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer
- Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study
- Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic
- Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial in Women at Least 50 Years of Age With Early Breast Cancer
- Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
- Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve
- Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression
- Mammary Gland Density Predicts the Cancer Inhibitory Activity of the N-3 to N-6 Ratio of Dietary Fat
- Mammographic Density Reduction Is a Prognostic Marker of Response to Adjuvant Tamoxifen Therapy in Postmenopausal Patients With Breast Cancer
- Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial
- Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone
- Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells
- Molecular Pathways: Digoxin use and the estrogen-sensitive cancers: risks and possible therapeutic implications
- Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen
- Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark
- Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
- Obesity Linked to Worse Outcomes in Early Breast Cancer Treatment
- Pharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor
- Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations
- Phytoestrogens and breast cancer: a complex story
- Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model
- Pomegranate extract demonstrate a selective estrogen receptor modulator profile in human tumor cell lines and in vivo models of estrogen deprivation
- Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells
- Potential mechanisms whereby the lignan or oil components of flaxseed, alone or in combination with tamoxifen exert their effect on breast cancer
- Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells
- Primary endocrine therapy for early operable primary breast cancer in elderly women: Survival analysis of a large series from a single institution
- Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer
- Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer
- Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro
- Reduced Bioavailability of Tamoxifen and its Metabolite 4-Hydroxytamoxifen After Oral Administration with Biochanin A (an Isoflavone) in Rats
- Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
- Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells
- Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects
- Risk factors for fractures in patients on hormonal therapies for breast cancer and DCIS
- Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients
- Risk of second breast cancer according to estrogen receptor status and family history
- Second malignancies after breast cancer: the impact of different treatment modalities
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
- Selenium disrupts estrogen receptor signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells
- Sexual Function after Breast Cancer
- Soy Food Intake and Breast Cancer Survival
- Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis
- Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha
- Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer
- Surgery for widely disseminated breast cancer: prolonged control by excision of metastases
- Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Long term results of the Italian Tamoxifen Anastrozole trial
- Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism
- Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer
- Tamoxifen Alters the Plasma Concentration of Molecules Associated with Cardiovascular Risk in Women with Breast Cancer Undergoing Chemotherapy
- Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group
- Tamoxifen and Curcumin Binding to Serum Albumin. Spectroscopic Study
- Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo
- Tamoxifen, flaxseed and the lignan enterolactone increase stroma and cancer cell derived IL-1Ra and decrease tumor angiogenesis in estrogen dependent breast cancer
- Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer
- The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study
- The Effect of the Phytoestrogens Genistein, Daidzein, and Equol on the Growth of Tamoxifen-Resistant T47D/PKCα
- The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L)
- The phytochemical lindleyin, isolated from Rhei rhizoma, mediates hormonal effects through estrogen receptors
- The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
- Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
- Tualang Honey Promotes Apoptotic Cell Death Induced by Tamoxifen in Breast Cancer Cell Lines
- Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting
- Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study
- Vitamin E Increases Biomarkers of Estrogen Stimulation When Taken With Tamoxifen
- Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer
- Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study
- Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer